IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 974天前
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 525天前
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 707天前
Euro Falls Against Majors

Euro Falls Against Majors

The euro weakened against other major currencies in the pre-European session on Tuesday.
RTTNews | 1小時5分鐘前
European Economic News Preview: UK Mortgage Approvals Data Due

European Economic News Preview: UK Mortgage Approvals Data Due

Mortgage approvals from the UK and flash GDP from Spain are the top economic news due on Tuesday. At 3.00 am ET, Spain's statistical office INE publishes flash GDP data and retail sales figures. The economy is forecast to grow at a steady pace of 0.6 percent in the second quarter.
RTTNews | 1小時42分鐘前
Australian Market Trims Early Losses In Mid-market

Australian Market Trims Early Losses In Mid-market

The Australian stock market is trimming is early losses in mid-market trading on Tuesday, reversing the slight gains in the previous session, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is staying well below the 8,700 level, with weakness in financial and technology stocks partially offset by some gains in energy stocks.
RTTNews | 4小時13分鐘前
Asian Markets Trade Mostly Lower

Asian Markets Trade Mostly Lower

Asian stock markets are trading mostly lower on Tuesday, following the mixed cues from Wall Street overnight, as traders remain cautious ahead of the U.S. interest rate decision later in the week and as they await the outcome of the U.S.-China trade talks. Meanwhile, several European leaders voiced concerns over the EU-U.S. trade deal, calling it 'lopsided' and 'unsustainable'.
RTTNews | 4小時20分鐘前